Elraglusib

Generic Name: Elraglusib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₃FN_₂O_₅

CAS Number: 1034895-42-5

Unique Ingredient Identifier: ND1SOF0DLU

Background: Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

ACTUATE THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ELRAGLUSIB TARGETING PANCREATIC CANCER

Actuate Therapeutics received FDA Orphan Drug Designation for elraglusib, targeting pancreatic cancer. Elraglusib, a GSK-3β inhibitor, is in phase 2 trials, showing promise in combination therapies for advanced pancreatic cancer, addressing a critical unmet medical need with less than 10% survival at 5 years.

Related Clinical Trials:

9-ING-41 in Patients with Advanced Cancers

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy